PEPTIDES: THE 2026 FDA CRACKDOWN CONTROVERSYWhy this is MASSIVE SEO RIGHT NOW BPC 157 banned Compounded Drug Products That Are Essentially Copies of Approved Drug Products Under Section 503B of the Federal Food, Drug, and Last week @fda sends out clarification on who can and cannot compound #glp1 like #tirzeaptide and #semaglutide and this week ProRx 503b shuts down GLP 1 compounding while @martymakary is photographed holding bootleg # The Blacklisting of Peptides FDA mulls compounding for peptides previously flagged over safety risks BioSpace